Presymptom Health Limited

Presymptom Health machine-learning-derived blood tests investigate the patient – rather than the pathogen – allowing us to rule out infection or sepsis. Existing technologies are slow (up to 3 days to result) and fail to distinguish pathogenicity from colonization. Presymptom Health is developing a patented set of assays to support early diagnosis and enhanced antibiotic stewardship to combat the Anti Microbial Resistance (AMR) crisis. Trained from blood samples collected over 15 years, these samples included thousands of patients, some of whom developed infections and sepsis. The first product, InfectiClear®, will be available from 2025.